Baloxavir marboxil
Antiviral medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Baloxavir marboxil?
Summarize this article for a 10 year old
Baloxavir marboxil, sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B.[4] It was approved for medical use both in Japan and in the United States in 2018,[7][8][9] and is taken as a single dose by mouth.[4] It may reduce the duration of flu symptoms by about a day, but is prone to selection of resistant mutants that render it ineffectual.[10][unreliable medical source?]
Clinical data | |
---|---|
Trade names | Xofluza |
Other names | BXM (S-033188), BXA (S-033447) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618062 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C27H23F2N3O7S |
Molar mass | 571.55 g·mol−1 |
3D model (JSmol) | |
| |
|
Baloxavir marboxil was developed as a prodrug strategy, with its metabolism releasing the active agent, baloxavir acid (BXA). Baloxavir acid then functions as enzyme inhibitor, targeting the influenza virus' cap-dependent endonuclease activity, used in "cap snatching" by the virus' polymerase complex, a process essential to its life-cycle.[11]
The most common side effects of baloxavir marboxil include diarrhea, bronchitis, nausea, sinusitis, and headache.[12]
The US Food and Drug Administration (FDA) considers baloxavir marboxil to be a first-in-class medication.[13]